RN
Rajesh Nandwani
About Rajesh Nandwani
Data last updated:
Rajesh Nandwani is a Director at Rajesh Specialities Private Limited (since 2020), Director at Zorg Life Sciences (India) Private Limited (since 2024) and Director at Rabs Buildcon Private Limited (since 2012), and holds 5 more current directorships. The companies operate in Pharma, Real Estate and Construction and Healthcare. The 4 current companies with reported revenue have a combined latest revenue of ₹85.34 Cr; the largest is Rajesh Specialities Private Limited at ₹66.16 Cr (FY 2025). Earlier, Rajesh Nandwani was a Director at Trilok Pharma Private Limited (2019–2024) and Director at Ethnotech Pharmaceuticals Private Limited (from 2004) and 1 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 06 Aug 2020 | 2020 | ₹66.16 Cr (FY 2025) | Active | |
| Director | 20 Sep 2024 | 2014 | ₹15.93 Cr (FY 2024) | Active | |
| Director | 21 Feb 2012 | 2012 | ₹3.25 Cr (FY 2025) | Active | |
| Director | 20 Jan 2023 | 2023 | ₹54,389 (FY 2025) | Active | |
| Director | 13 Jun 2025 | 2025 | Active | ||
| Director | 30 Apr 2025 | 2025 | Active | ||
| Director | 10 Mar 2025 | 2025 | Active | ||
| Director | 09 Aug 2023 | 2023 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 05 Nov 2019 | 2019 | ₹59.67 Cr (FY 2025) | Active | |
| Director | 01 May 2004 | 2002 | Strike Off | ||
| Director | 18 Nov 2019 | 2019 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Rajesh Nandwani
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rajesh Nandwani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rajesh Nandwani
Rajesh Nandwani currently holds 8 directorships: Rajesh Specialities Private Limited (Director, since 06 Aug 2020, revenue ₹66.16 Cr (FY 2025)); Zorg Life Sciences (India) Private Limited (Director, since 20 Sep 2024, revenue ₹15.93 Cr (FY 2024)); Rabs Buildcon Private Limited (Director, since 21 Feb 2012, revenue ₹3.25 Cr (FY 2025)); Pharmendia Healthcare Private Limited (Director, since 20 Jan 2023, revenue ₹54,389 (FY 2025)); Marks Realty Developers Private Limited (Director, since 13 Jun 2025); and 3 more.
Rajesh Nandwani was first appointed on 01 May 2004 as Director at Ethnotech Pharmaceuticals Private Limited. The most recent appointment on record is 13 Jun 2025 at Marks Realty Developers Private Limited.
The 4 current companies of Rajesh Nandwani that report revenue have a combined latest revenue of ₹85.34 Cr: Rajesh Specialities Private Limited ₹66.16 Cr (FY 2025); Zorg Life Sciences (India) Private Limited ₹15.93 Cr (FY 2024); Rabs Buildcon Private Limited ₹3.25 Cr (FY 2025); Pharmendia Healthcare Private Limited ₹54,389 (FY 2025).
Rajesh Nandwani held 3 earlier board appointments: Trilok Pharma Private Limited (Director, 05 Nov 2019 to 21 Sep 2024); Ethnotech Pharmaceuticals Private Limited (Director, from 01 May 2004); Savitri Leela Private Limited (Director, from 18 Nov 2019).
The current boards of Rajesh Nandwani's companies include Kishore Kumar Nandwani (Rajesh Specialities Private Limited), Manoj Adnani (Zorg Life Sciences (India) Private Limited), Aman Sohaney (Rabs Buildcon Private Limited), Anil Kumar Nandwani (Rabs Buildcon Private Limited), Arpit Agrawal (Rabs Buildcon Private Limited), Brajesh Sohaney (Rabs Buildcon Private Limited), among others.